Nyob rau hauv lub xub ntiag ntawm 2.8 mM D-qabzib, beta-D-glucose pentaacetate (1. 7 mM) augmented insulin tso tawm los ntawm cais nas pancreatic islets ntau tshaj alpha-D-glucose pentaacetate.Ib yam li ntawd, qhov kev nce ntxiv hauv cov tshuaj insulin evoked los ntawm nateglinide (0.01 mM) yog siab dua hauv cov islets raug beta- ntau dua li alpha-D-glucose pentaacetate.Nyob rau hauv qhov tseeb, nyob rau hauv lub xub ntiag ntawm 2.8 mM unesterified D-glucose, alpha-L-glucose pentaacetate, tab sis tsis beta-L-glucose pentaacetate, ho augmented insulin ntau lawm.Qhov siab dua insulinotropic potency ntawm beta-anomer ntawm D-glucose pentaacetate coincided nrog qhov tseeb hais tias nws ho nce qhov sib piv ntawm D-[U-14C] glucose oxidation thiab D-[5-3H] qabzib siv, whereas alpha-D. -glucose pentaacetate ua tsis tiav.Cov kev tshawb pom no tau txhais los txhawb lub tswv yim tias qhov kev txhawb nqa ntawm cov tshuaj insulin tso tawm los ntawm cov esters no feem ntau tshwm sim los ntawm lawv cov kev sib cuam tshuam ncaj qha nrog cov stereospecific receptor, nrog rau kev nyiam rau kev teeb tsa ntawm C1 ntau rau beta-D-glucose pentaacetate thiab alpha-L- qabzib pentaacetate.
